SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

FOSTER CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. NASDAQ:SGMT, a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today reported financial results for the quarter ended September 30…

SGMT
SquawkNews Desk

Related stories

Speaker Johnson Says Congress Developing Consensus on Limiting Chip Exports to China House Speaker Mike Johnson said Congress is developing consensus on limiting chip exports to China. L impact | REGULATION | Nov 12, 2026, 02:49 PM UTC US Sen. Warren: Commerce Sec. Lutnick Must Explain Export Control Loopholes L impact | REGULATION | Nov 12, 2026, 02:34 PM UTC EU Court Adviser Urges Review of Google AdSense Fine Decision An adviser to the EU’s top court said a lower tribunal should revisit its decision to scrap the fine against Google over AdSense. L impact | REGULATION | Nov 12, 2026, 02:02 PM UTC USTR Greer Says China Partially Fulfilling Promises Greer said China bought the agreed-upon amount of soybeans but had not fulfilled commitments on rare earths. L impact | REGULATION | Nov 12, 2026, 01:51 PM UTC USTR Greer Says He Wants Certainty on Tariffs L impact | REGULATION | Nov 12, 2026, 01:39 PM UTC Trump Threatens to Double Tariffs on Mexico Over Migrant Halt M impact | REGULATION | Nov 12, 2026, 01:37 PM UTC